(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 August 2014 (28.08.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/127906 A1

(51) International Patent Classification:
C07K 16/30 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/EP2014/000433

(22) International Filing Date:
18 February 2014 (18.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PCT/EP2013/000505
20 February 2013 (20.02.2013) EP

(71) Applicants: **GANYMED PHARMACEUTICALS AG** [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE). **TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ GEMEINNÜTZIGE GMBH** [DE/DE]; Langenbeckstrasse 1, Geb. 708, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **TÜRECI, Özlem**; Philipp-von-Zabern-Platz 1, 55116 Mainz (DE). **MITNACHT-KRAUS, Rita**; Taunusstrasse 45, 61169 Friedberg (DE). **WÖLL, Stefan**; Pommardstrasse 22a, 55299 Nackenheim (DE). **JACOBS, Stefan**; Friedenstrasse 7, 55252 Mainz-Kastel (DE). **HEINZ, Cornelia**; Auf den Elfmorgen 22, 55278 Dalheim (DE).

(74) Agents: **SCHNAPPAUF, Georg** et al.; Radlkoferstrasse 2, 81373 Munich (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii))*

— *with sequence listing part of description (Rule 5.2(a))*

WO 2014/127906 A1

(54) Title: COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

(57) Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.